Experimental infection and protection against ... - TI Pharma

Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1
Malaria vaccine Adjuvanted with Alhydrogel TM, Montanide ISA 720 or AS02
References
1. Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and
development: malaria. Vaccine 2007; 25:1567-1580.
2. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E et al. Duration of protection
with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum
disease in Mozambican children: single-blind extended follow-up of a randomised
controlled trial. Lancet 2005; 366:2012-2018.
3. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q et al. Safety of the
RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of
Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007;
370:1543-1551.
4. Mitchell GH, Thomas AW, Margos G, Dluzewski AR, Bannister LH. Apical
membrane antigen 1, a major malaria vaccine candidate, mediates the close
attachment of invasive merozoites to host red blood cells. Infect Immun 2004;
72:154-158.
5. Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody
response to apical membrane antigen 1. Infect Immun 2001; 69:3286-3294.
6. Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A et al. A role for apical
membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum
sporozoites. J Biol Chem 2004; 279:9490-9496.
7. Howell SA, Withers-Martinez C, Kocken CH, Thomas AW, Blackman MJ. Proteolytic
processing and primary structure of Plasmodium falciparum apical membrane
antigen-1. J Biol Chem 2001; 276: 31311-31320.
8. Remarque EJ, Faber BW, Kocken CH, Thomas AW. Apical membrane antigen 1: a
malaria vaccine candidate in review. Trends Parasitol 2008; 24:74-84.
9. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT et al. Phase I/IIa safety,
immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen,
multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis
1998; 177:1664-1673.
10. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP et al. Phase 1 clinical
trial of apical membrane antigen 1: an asexual blood-stage vaccine for
Plasmodium falciparum malaria. Infect Immun 2005; 73:3677-3685.
11. Schijns VE, Degen WG. Vaccine immunopotentiators of the future. Clin Pharmacol
Ther 2007; 82:750-755.
12. Keitel WA, Kester KE, Atmar RL, White AC, Bond NH et al. Phase I trial of two
recombinant vaccines containing the 19kd carboxy terminal fragment of
Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper
epitopes of tetanus toxoid. Vaccine 1999; 18:531-539.
53